non small lung cancer
Conditions
Interventions
research group:received the combined therapy of 125I brachytherapy and DP chemotherapy,
control group: DP chemotherapy
Sponsors
The First People's Hospital, Huaian (the First Hospital of Huaian Affiniated Nanjing Medical University)
Eligibility
Sex/Gender
All
Age
22 Years to 75 Years
Inclusion criteria
Inclusion criteria: 1. patients with locally recurrent stage III NSCLC within one year after receiving concurrent chemoradiotherapy; 2. time of survival was estimated to be longer than three months; 3. tumor diameter was less than 6 cm; 4. no severe liver insufficiency, renal insufficiency, heart diseases, diabetes, coagulation dysfunction, and other chronic diseases; 5. no severer chronic basic pulmonary diseases; 6. the Eastern Cooperative Oncology Group (ECOG) score 2; 7. tumor lesion had a suitable position for brachytherapy, which was confirmed by chest CT scanning; 8. patients and their families were intended to receive the treatments of this study; 9. patients didn't receive any radiotherapy and chemotherapy within 3 months of the study procedure. All patients were evaluated by the investigators of this study (including the oncologists, surgical specialists, and radiologists of Huai'an First People's Hospital Affiliated to Nanjing Medical University) and confirmed to be able to receive the second-line chemotherapy (doctaxel (60 mg/m2, at day 1) plus cisplatin (75 mg/m2, at day 2)) and CT-guided radioactive 125I seed implantation.
Exclusion criteria
Exclusion criteria: PS>2 score ,survival time more than 3m.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| progression-free survival;the time of local regional control; | — |
Countries
China
Contacts
Public ContactHe Jingdong
Outcome results
None listed